Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov 17;47(11):952.
doi: 10.3390/cimb47110952.

Maternal and Fetal SERPINA3 Polymorphisms and Risk of Preeclampsia: A Dyad and Triad Based Case-Control Study

Affiliations

Maternal and Fetal SERPINA3 Polymorphisms and Risk of Preeclampsia: A Dyad and Triad Based Case-Control Study

Hsi-Hsuan Yang et al. Curr Issues Mol Biol. .

Abstract

Serine protease inhibitor A3 (SERPINA3), also called α-1-antichymotrypsin, is a serine protease involved in placental dysfunction. This study examines SERPINA3 polymorphisms and haplotypes for associations with maternal hypertensive disorders of pregnancy (HDPs) and preeclampsia with severe features (sPE) or Hemolysis, Elevated Liver Enzymes, and Low Platelet (HELLP) syndrome in mother-baby dyads (HDP) and mother-father-baby triads (sPE/HELLP). This retrospective case-control study examined two patient cohorts, HDPs and severe PE/HELLP syndrome. The HDP population included cases (n = 142) and controls (n = 168) of mother-baby dyads recruited from a large, urban, safety-net hospital in Los Angeles. The sPE/HELLP syndrome population included cases (n = 189) and controls (n = 28) of mother-father-baby triads recruited through HELLP syndrome research websites. Cases were verified by medical chart abstraction when possible. Two SERPINA3 SNPs, rs4934 and rs1884082, were genotyped from saliva samples, mouthwash, or buccal swabs. The Haplin package in R was used to perform genetic association analyses. No evidence of increased risk related to individual SERPINA3 SNPs or haplotypes for the developing HDPs or sPE/HELLP was found in individual nor combined cohorts. In the HDP cohort, the g-a haplotype (relative to T-G haplotype) was borderline significant for increased risk of HDPs when carried by the child (double dose: RR = 1.58, 95% CI: (1.00, 2.52), p = 0.05). We observed significant parent-of-origin (PoO) effects in the combined cohort: specifically, an increased risk of HDPs/sPE/HELLP if the mother carries a double copy for both rs4934 (RR = 3.03, 95% CI (1.50, 6.09), p < 0.01) and rs1884082 (RR = 2.38, 95% CI (1.22, 4.71), p = 0.01). A reduced risk of HDPs/sPE/HELLP was observed for rs4934 (RR = 0.54, 95% CI (0.31, 0.98), p = 0.04) and rs1884082 (RR = 0.52, 95% CI (0.30, 0.91), p = 0.02) with child carriage of the maternally inherited allele. In contrast, child carriage of a paternally inherited copy of the variant allele for rs4934 increased risk of HDPs/sPE/HELLP (RR = 1.54, 95% CI (1.09, 2.20), p = 0.02). There was no evidence that SERPINA3 gene polymorphisms and haplotypes were associated with risk of HDPs or sPE/HELLP. However, significant PoO effects were observed in the combined cohort analysis, with child carriage of rs4934 that is maternally inherited decreasing HDPs/sPE/HELLP risk while a paternally inherited copy increases risk, suggesting a role for maternal-fetal genomic incompatibility.

Keywords: HELLP syndrome; genetics; parent-of-origin; polymorphism; preeclampsia.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Participant flow chart in HDP population.
Figure 2
Figure 2
Participant flow in severe PE/HELLP syndrome population.

References

    1. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am. J. Obstet. Gynecol. 2000;183:S1–S22. doi: 10.1067/mob.2000.107928. - DOI - PubMed
    1. US Preventive Services Task Force. Barry M.J., Nicholson W.K., Silverstein M., Cabana M.D., Chelmow D., Coker T.R., Davis E.M., Donahue K.E., Jaén C.R., et al. Screening for Hypertensive Disorders of Pregnancy: US Preventive Services Task Force Final Recommendation Statement. JAMA. 2023;330:1074–1082. doi: 10.1001/jama.2023.16991. - DOI - PubMed
    1. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet. Gynecol. 2013;122:1122–1131. doi: 10.1097/01.AOG.0000437382.03963.88. - DOI - PubMed
    1. Sep S., Verbeek J., Koek G., Smits L., Spaanderman M., Peeters L. Clinical differences between early-onset HELLP syndrome and early-onset preeclampsia during pregnancy and at least 6 months postpartum. Am. J. Obstet. Gynecol. 2010;202:271.e1–271.e5. doi: 10.1016/j.ajog.2009.10.874. - DOI - PubMed
    1. Mathew R., Devanesan B.P., Sreedevi N. Prevalence of hypertensive disorders of pregnancy, associated factors, and pregnancy complications in a primigravida population. Gynecol. Obstet. Clin. Med. 2023;3:119–123. doi: 10.1016/j.gocm.2023.01.002. - DOI

LinkOut - more resources